Mylan Inc (MYL) 55.85 $MYL
Mylan Sees A Sentiment Shift From A Top 3 Institutional Holder
Dallas Salazar - at Seeking Alpha - Fri Feb 13, 10:52AM CST
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Meet the 23 Women Who Are CEOs of S&P 500 Companies
at The Street - Thu Feb 12, 9:50AM CST
Just 4.6% of the biggest companies in the country are run by women.
RAI: 71.86 (-1.23), GD: 137.61 (-0.54), LMT: 196.95 (-0.53), AVP: 9.08 (+0.39), FTR: 8.38 (+0.01), MDLZ: 36.78 (-0.20), HCP: 42.87 (+0.20), DUK: 79.84 (-1.22), MYL: 55.85 (+1.34), XRX: 13.77 (+0.20), KEY: 14.11 (-0.08), SRE: 105.56 (-1.11), HPQ: 38.56 (+0.19), VTR: 76.61 (-0.41), ORCL: 43.93 (+0.04), PEP: 99.13 (-1.14), YHOO: 44.42 (+0.50), IBM: 160.40 (+1.88), GCI: 34.77 (-0.07), CPB: 46.88 (-0.84), DD: 76.18 (-0.11), GM: 37.62 (-0.40), ROST: 96.18 (+0.51)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Mylan Insiders Sell $118.4 Million In Stock
Dallas Salazar - at Seeking Alpha - Tue Feb 10, 2:45PM CST
MYL: 55.85 (+1.34)
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:02PM CST
Mylan (MYL) confirms patent challenge for generic version of Nexavar, and it expects exclusivity.
IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 46.09 (+0.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), EPRS: 7.67 (+0.67), TEVA: 56.77 (-0.58), HSP: 87.35 (unch)
Mylan Schedules Fourth Quarter and Year End 2014 Financial Results Conference Call and Live Webcast
PR Newswire - Mon Feb 09, 10:45AM CST
Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Monday, March 2, 2015, at 4:30 p.m. ET, to review the company's financial results for the fourth quarter and year ended Dec. 31, 2014. The company also will be providing its financial guidance for 2015. Mylan will release its financial results on March 2 after the market closes.
MYL: 55.85 (+1.34)
Mylan Confirms First-to-File Patent Challenge Relating to NEXAVAR®
PR Newswire - Mon Feb 09, 10:00AM CST
Mylan Inc. (Nasdaq: MYL) today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Sorafenib Tablets, 200 mg. This product is the generic version of NEXAVAR®, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
MYL: 55.85 (+1.34)
Teva Pharmaceutical's Strategy Proves to be Brilliant
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 06, 12:03PM CST
Source: Teva Pharmaceuticals When Teva Pharmaceutical 's patent on its top-selling multiple sclerosis drug Copaxone expired last May, investors fled in fear that biosimilars under development at Novartis ' Sandoz unit and Mylan Inc . would...
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Three Reasons To Let Akorn Fall Into Your Portfolio
at Investor's Business Daily - Fri Feb 06, 10:11AM CST
With a 99 IBD Composite Rating, a stock price trading at all-time highs and a recent run of robust financial growth, generic drug maker Akorn (AKRX) is already a top stock. It might show even more strength in future quarters, thanks to several trends...
PRGO: 150.90 (+0.22), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Pfizer's shopping cart still has plenty of room
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:20AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), HSP: 87.35 (unch)
Mylan's Recent Buys And News Have Spurred Huge Insider Buying
David White - at Seeking Alpha - Thu Feb 05, 11:12AM CST
ABT: 46.09 (+0.87), GILD: 101.90 (+1.10), MYL: 55.85 (+1.34), TBPH: 18.51 (+0.28)
Mylan, Theravance Ink Deal to Develop, Market COPD Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 5:03PM CST
Mylan Inc. (MYL) and Theravance will collaborate for the development of TD-4208 for COPD and other respiratory diseases and its commercialization (upon FDA approval).
IPXL: 39.51 (+0.69), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), TBPH: 18.51 (+0.28)
Mylan to Buy Famy Care Businesses, Boost Women's Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:35PM CST
Mylan (MYL) is set to acquire Indian drug maker Famy Care Limited's certain female reproductive health care businesses to expand its line of women's health portfolio.
MNK: 115.01 (+2.51), IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Hogging the Limelight: New Research on Exxon Mobil, You On Demand, Mylan, Verizon, and Intel
PR Newswire - Tue Feb 03, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Exxon Mobil (NYSE: XOM), You On Demand (NASDAQ: YOD), Mylan (NASDAQ: MYL), Verizon (NYSE: VZ), and Intel (NASDAQ: INTC). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
MYL: 55.85 (+1.34), XOM: 93.37 (+1.00), YOD: 2.22 (+0.04), INTC: 34.36 (+0.23), VZ: 49.31 (-0.21)
Why Theravance Biopharma Inc Shares Soared Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 02, 3:57PM CST
What: Shares of Theravance Biopharma jumped by more than 10% in early trading Monday before finishing the day up nearly 7% on news that it had inked a collaborative deal with generics Goliath Mylan to develop a treatment for COPD. So What: ...
MYL: 55.85 (+1.34), GSK: 47.94 (+1.99), TBPH: 18.51 (+0.28)
What The Mylan Partnership Means For Theravance Biopharma
Early Retiree - at Seeking Alpha - Mon Feb 02, 3:40PM CST
MYL: 55.85 (+1.34), TBPH: 18.51 (+0.28)
Mylan Makes Deals In Women's Health, Lung Disease
at Investor's Business Daily - Mon Feb 02, 11:48AM CST
Generic-drug giant Mylan (MYL) announced Monday that it's buying $800 million in assets of an India-based women's-health company. Mylan also bought into a lung-disease drug candidate. Mylan agreed to pay $750 million upfront plus up to $50 million in...
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), GSK: 47.94 (+1.99), THRX: 14.85 (+1.00), TBPH: 18.51 (+0.28)
Stock Futures Trim Early Gains; Exxon Mobil Up After Earnings
at Investor's Business Daily - Mon Feb 02, 8:10AM CST
Stock futures trimmed gains ahead of Monday's Groundhog Day session, as rising oil prices and weak consumer spending data pushed and pulled on early trade. Dow futures had halved their early gain to trade 34 points above fair market value. S&P 500...
SYY: 39.54 (-0.12), MYL: 55.85 (+1.34), XOM: 93.37 (+1.00), SN: 15.21 (-0.12), SDRL: 12.32 (-0.70), BHI: 64.31 (+1.93)
Mylan buying some women's health care businesses for $750M
AP - Mon Feb 02, 6:23AM CST
PITTSBURGH (AP) — Generic drugmaker Mylan is buying some women's health care businesses from Indian health care company Famy Care Ltd. for $750 million.
MYL: 55.85 (+1.34)
Mylan Sees A Sentiment Shift From A Top 3 Institutional Holder
Dallas Salazar - at Seeking Alpha - Fri Feb 13, 10:52AM CST
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Meet the 23 Women Who Are CEOs of S&P 500 Companies
at The Street - Thu Feb 12, 9:50AM CST
Just 4.6% of the biggest companies in the country are run by women.
RAI: 71.86 (-1.23), GD: 137.61 (-0.54), LMT: 196.95 (-0.53), AVP: 9.08 (+0.39), FTR: 8.38 (+0.01), MDLZ: 36.78 (-0.20), HCP: 42.87 (+0.20), DUK: 79.84 (-1.22), MYL: 55.85 (+1.34), XRX: 13.77 (+0.20), KEY: 14.11 (-0.08), SRE: 105.56 (-1.11), HPQ: 38.56 (+0.19), VTR: 76.61 (-0.41), ORCL: 43.93 (+0.04), PEP: 99.13 (-1.14), YHOO: 44.42 (+0.50), IBM: 160.40 (+1.88), GCI: 34.77 (-0.07), CPB: 46.88 (-0.84), DD: 76.18 (-0.11), GM: 37.62 (-0.40), ROST: 96.18 (+0.51)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Mylan Insiders Sell $118.4 Million In Stock
Dallas Salazar - at Seeking Alpha - Tue Feb 10, 2:45PM CST
MYL: 55.85 (+1.34)
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:02PM CST
Mylan (MYL) confirms patent challenge for generic version of Nexavar, and it expects exclusivity.
IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 46.09 (+0.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), EPRS: 7.67 (+0.67), TEVA: 56.77 (-0.58), HSP: 87.35 (unch)
Mylan Schedules Fourth Quarter and Year End 2014 Financial Results Conference Call and Live Webcast
PR Newswire - Mon Feb 09, 10:45AM CST
Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Monday, March 2, 2015, at 4:30 p.m. ET, to review the company's financial results for the fourth quarter and year ended Dec. 31, 2014. The company also will be providing its financial guidance for 2015. Mylan will release its financial results on March 2 after the market closes.
MYL: 55.85 (+1.34)
Mylan Confirms First-to-File Patent Challenge Relating to NEXAVAR®
PR Newswire - Mon Feb 09, 10:00AM CST
Mylan Inc. (Nasdaq: MYL) today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Sorafenib Tablets, 200 mg. This product is the generic version of NEXAVAR®, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
MYL: 55.85 (+1.34)
Teva Pharmaceutical's Strategy Proves to be Brilliant
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 06, 12:03PM CST
Source: Teva Pharmaceuticals When Teva Pharmaceutical 's patent on its top-selling multiple sclerosis drug Copaxone expired last May, investors fled in fear that biosimilars under development at Novartis ' Sandoz unit and Mylan Inc . would...
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Three Reasons To Let Akorn Fall Into Your Portfolio
at Investor's Business Daily - Fri Feb 06, 10:11AM CST
With a 99 IBD Composite Rating, a stock price trading at all-time highs and a recent run of robust financial growth, generic drug maker Akorn (AKRX) is already a top stock. It might show even more strength in future quarters, thanks to several trends...
PRGO: 150.90 (+0.22), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Pfizer's shopping cart still has plenty of room
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:20AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), HSP: 87.35 (unch)
Mylan's Recent Buys And News Have Spurred Huge Insider Buying
David White - at Seeking Alpha - Thu Feb 05, 11:12AM CST
ABT: 46.09 (+0.87), GILD: 101.90 (+1.10), MYL: 55.85 (+1.34), TBPH: 18.51 (+0.28)
Mylan, Theravance Ink Deal to Develop, Market COPD Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 5:03PM CST
Mylan Inc. (MYL) and Theravance will collaborate for the development of TD-4208 for COPD and other respiratory diseases and its commercialization (upon FDA approval).
IPXL: 39.51 (+0.69), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), TBPH: 18.51 (+0.28)
Mylan to Buy Famy Care Businesses, Boost Women's Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:35PM CST
Mylan (MYL) is set to acquire Indian drug maker Famy Care Limited's certain female reproductive health care businesses to expand its line of women's health portfolio.
MNK: 115.01 (+2.51), IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Hogging the Limelight: New Research on Exxon Mobil, You On Demand, Mylan, Verizon, and Intel
PR Newswire - Tue Feb 03, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Exxon Mobil (NYSE: XOM), You On Demand (NASDAQ: YOD), Mylan (NASDAQ: MYL), Verizon (NYSE: VZ), and Intel (NASDAQ: INTC). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
MYL: 55.85 (+1.34), XOM: 93.37 (+1.00), YOD: 2.22 (+0.04), INTC: 34.36 (+0.23), VZ: 49.31 (-0.21)
Why Theravance Biopharma Inc Shares Soared Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 02, 3:57PM CST
What: Shares of Theravance Biopharma jumped by more than 10% in early trading Monday before finishing the day up nearly 7% on news that it had inked a collaborative deal with generics Goliath Mylan to develop a treatment for COPD. So What: ...
MYL: 55.85 (+1.34), GSK: 47.94 (+1.99), TBPH: 18.51 (+0.28)
What The Mylan Partnership Means For Theravance Biopharma
Early Retiree - at Seeking Alpha - Mon Feb 02, 3:40PM CST
MYL: 55.85 (+1.34), TBPH: 18.51 (+0.28)
Mylan Makes Deals In Women's Health, Lung Disease
at Investor's Business Daily - Mon Feb 02, 11:48AM CST
Generic-drug giant Mylan (MYL) announced Monday that it's buying $800 million in assets of an India-based women's-health company. Mylan also bought into a lung-disease drug candidate. Mylan agreed to pay $750 million upfront plus up to $50 million in...
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), GSK: 47.94 (+1.99), THRX: 14.85 (+1.00), TBPH: 18.51 (+0.28)
Stock Futures Trim Early Gains; Exxon Mobil Up After Earnings
at Investor's Business Daily - Mon Feb 02, 8:10AM CST
Stock futures trimmed gains ahead of Monday's Groundhog Day session, as rising oil prices and weak consumer spending data pushed and pulled on early trade. Dow futures had halved their early gain to trade 34 points above fair market value. S&P 500...
SYY: 39.54 (-0.12), MYL: 55.85 (+1.34), XOM: 93.37 (+1.00), SN: 15.21 (-0.12), SDRL: 12.32 (-0.70), BHI: 64.31 (+1.93)
Mylan buying some women's health care businesses for $750M
AP - Mon Feb 02, 6:23AM CST
PITTSBURGH (AP) — Generic drugmaker Mylan is buying some women's health care businesses from Indian health care company Famy Care Ltd. for $750 million.
MYL: 55.85 (+1.34)
